Neurocrine Biosciences Initiates Phase 1 Clinical Study for NBIP-01435

Neurocrine Biosciences has announced the initiation of a Phase 1 clinical study for NBIP-01435, a long-acting corticotropin-releasing factor type 1 receptor antagonist.

The study is a key milestone in the development of NBIP-01435, a potential treatment for a specific medical condition.

Key Details of the Study

• The study is a Phase 1 clinical trial, designed to assess the safety and tolerability of NBIP-01435 in healthy volunteers.
• The study will evaluate the pharmacokinetics and pharmacodynamics of NBIP-01435.

Company Stock Performance

Neurocrine Biosciences’ stock price has fluctuated within the past year, with the following notable milestones:

• 52-week high: $157.98 USD on July 31, 2024
• 52-week low: $84.23 USD on April 8, 2025
• Closing stock price on June 30, 2025: $125.69 USD